In 1970, Cisplatin, a platinum-containing anticancer compound with unique biologic effects, entered clinical trials. On Dec. 19, 1978, Cisplatin was approved for use in testicular and ovarian cancers by the U.S. Food and Drug Administration. Cisplatin was approved for use in testicular and ovarian cancers.

It has been used for treatment of numerous human cancers including bladder, head and neck, lung, ovarian, and testicular cancers. It is effective against various types of cancers, including carcinomas, germ cell tumors, lymphomas, and sarcomas.